{
    "clinical_study": {
        "@rank": "16841", 
        "brief_summary": {
            "textblock": "The study is intended to examine the efficacy of fluconazole for the treatment of\n      coccidioidal meningitis in patients with new onset of infection, relapse of previous\n      infection, or failed previous therapy. Drug efficacy, safety and tolerance will be examined."
        }, 
        "brief_title": "Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis", 
        "condition": [
            "Meningitis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Meningitis", 
                "Coccidioidomycosis", 
                "Meningitis, Fungal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Immunosuppressive therapy including corticosteroids and/or cytotoxic agents.\n\n          -  Antiviral therapy (e.g., zidovudine (AZT)).\n\n          -  Prophylaxis for Pneumocystis carinii pneumonia (PCP).\n\n          -  Any exceptions to use of concomitant medications must be approved by Pfizer Central\n             Research prior to study entry.\n\n        Concurrent Treatment:\n\n        Allowed:\n\n          -  Radiation therapy for mucocutaneous Kaposi's sarcoma.\n\n        Patients must:\n\n          -  Be clinically judged to be in need of treatment for coccidioidal meningitis.\n\n          -  Have > 1 week life expectancy.\n\n          -  Allowed:\n\n          -  Immunocompromised patients.\n\n          -  Patients with renal disease will have the dose of fluconazole adjusted and serum\n             levels may be monitored.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Amphotericin B.\n\n          -  Ketoconazole.\n\n          -  Miconazole.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Current antifungal infection that is responding to another agent. Findings of\n             improvement include one of the following, while on other therapy (without subsequent\n             relapse of the item):\n\n          -  CSF culture conversion from positive to negative.\n\n          -  OR\n\n          -  CSF antibody titer decrease of at least one dilution.\n\n          -  OR\n\n          -  Improvement in signs and symptoms of meningitis.\n\n          -  Have received more than minimal systemic antifungal therapy (see Patient Inclusion\n             Criteria), unless they meet criteria for previous treatment failure or relapse. They\n             must not have received this therapy since the time relapse or failure was documented,\n             except for minimal antifungal therapy allowed in Patient Inclusion Criteria.\n\n          -  Immediately life-threatening coccidioidomycosis defined as infection of such a degree\n             of clinical severity that the patient would be expected to die within 1 week, if\n             untreated, based on clinical judgment.\n\n          -  Experienced a prior allergic reaction or major side effect from an imidazole or\n             triazole compound.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Barbiturates.\n\n          -  Phenytoin.\n\n          -  Oral hypoglycemics.\n\n          -  Coumadin type anticoagulants.\n\n          -  Other systemic or intrathecal antifungal therapy.\n\n          -  Other experimental agents with exceptions noted in concomitant medications section.\n\n          -  Any exceptions to these prohibitions of concomitant medications must be approved by\n             Pfizer Central Research prior to study entry.\n\n        Patients with the following are excluded:\n\n          -  Are responding or are improving on current antifungal therapy with another agent.\n\n          -  Have received more than minimal systemic antifungal therapy (see Patient Inclusion\n             Criteria), unless they meet criteria for previous treatment failure or relapse. They\n             must not have received this therapy since the time relapse or failure was documented,\n             except for minimal antifungal therapy allowed in Patient Inclusion Criteria.\n\n          -  Immediately life-threatening coccidioidomycosis defined as infection of such a degree\n             of clinical severity that the patient would be expected to die within 1 week, if\n             untreated, based on clinical judgment.\n\n          -  Experienced a prior allergic reaction or major side effect from an imidazole or\n             triazole compound."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002010", 
            "org_study_id": "012P", 
            "secondary_id": "056-170"
        }, 
        "intervention": {
            "intervention_name": "Fluconazole", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Fluconazole"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Meningitis", 
            "Fluconazole", 
            "Coccidioidin", 
            "Acquired Immunodeficiency Syndrome", 
            "Coccidioidomycosis"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724"
                    }, 
                    "name": "Tucson Veterans Administration Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92102"
                    }, 
                    "name": "HIV Research Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78284"
                    }, 
                    "name": "Audie L Murphy Veterans Administration Hosp"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002010"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1992"
    }, 
    "geocoordinates": {
        "Audie L Murphy Veterans Administration Hosp": "29.424 -98.494", 
        "HIV Research Group": "32.715 -117.157", 
        "Tucson Veterans Administration Med Ctr": "32.222 -110.926"
    }
}